SuperworthDanaher profit margin DHR
Gross, operating and net profit as a share of revenue over the last twelve months, from 2009.
- Net margin, 12 months
- 15.9%
- Operating margin, 12 months
- 20.4%
- Net margin on a year earlier
- +1.7 pts
- Peer median
- 16.3%
Over the twelve months to Jun 26, 2026, Danaher kept 15.9% of its revenue as net profit, with an operating margin of 20.4% and a gross margin of 58.5%.
Five years earlier its net margin was 21.0%.
The median for 10 diagnostics and research stocks of a similar size is 16.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 14.7% | 19.1% | 59.1% |
| FY2024 | 16.3% | 20.4% | 59.5% |
| FY2023 | 19.9% | 21.8% | 58.7% |
| FY2022 | 27.1% | 28.3% | 60.8% |
| FY2021 | 21.8% | 25.3% | 61.0% |
| FY2020 | 16.4% | 19.0% | 56.0% |
| FY2019 | 16.8% | 18.3% | 55.7% |
| FY2018 | 15.5% | 17.9% | 55.8% |
| FY2017 | 13.6% | 16.3% | 55.6% |
| FY2016 | 15.1% | 16.3% | 55.3% |
| FY2015 | 23.3% | 15.0% | 53.8% |
| FY2014 | 13.6% | 17.5% | 51.6% |
| FY2013 | 14.1% | 17.1% | 52.1% |
| FY2012 | 13.1% | 17.3% | 51.6% |
| FY2011 | 13.5% | 16.3% | 50.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 15.9% | +1.7 pts | 20.4% | |
| Q1 FY26 | 14.9% | −0.9 pts | 19.2% | |
| Q4 FY25 | 14.7% | −1.6 pts | 19.1% | |
| Q3 FY25 | 14.4% | −2.0 pts | 19.0% | |
| Q2 FY25 | 14.2% | −3.6 pts | 18.4% | |
| Q1 FY25 | 15.8% | −2.7 pts | 20.3% | |
| Q4 FY24 | 16.3% | −3.6 pts | 20.4% | |
| Q3 FY24 | 16.4% | −7.6 pts | 20.1% | |
| Q2 FY24 | 17.8% | −7.2 pts | 21.2% | |
| Q1 FY24 | 18.5% | −8.1 pts | 21.1% | |
| Q4 FY23 | 19.9% | −7.1 pts | 21.8% | |
| Q3 FY23 | 24.0% | −0.4 pts | 23.8% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Danaher's size, closest first, today.
| Company | Profit margin |
|---|---|
| DHRDanaher | 15.9% |
| TMOThermo Fisher Scientific | 14.9% |
| AAgilent Technologies | 19.5% |
| IQVIQVIA | 8.1% |
| WATWaters | 3.6% |
| IDXXIDEXX Laboratories | 25.0% |
| ILMNIllumina | 18.4% |
| MTDMettler-Toledo International | 21.9% |
| DGXQuest Diagnostics | 9.2% |
| LHLabcorp | 7.0% |
| MEDPMedpace | 17.7% |
| Peer median | 16.3% |
Where Danaher ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Danaher
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.